Q3 2025 EPS Estimates for Illumina, Inc. (NASDAQ:ILMN) Lowered by Analyst

Illumina, Inc. (NASDAQ:ILMN) – Investment analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for shares of Illumina in a report issued on Tuesday, September 17th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will earn $1.12 per share for the quarter, down from their previous forecast of $1.13. The consensus estimate for Illumina’s current full-year earnings is $3.62 per share. Leerink Partnrs also issued estimates for Illumina’s FY2025 earnings at $4.39 EPS.

A number of other equities analysts also recently commented on ILMN. Piper Sandler cut their price objective on Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Jefferies Financial Group began coverage on shares of Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target on the stock. Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Wednesday, August 28th. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and upped their price target for the stock from $120.00 to $154.00 in a research report on Friday, August 16th. Finally, Daiwa America upgraded Illumina to a “strong-buy” rating in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $151.05.

Illumina Price Performance

Shares of Illumina stock opened at $130.21 on Wednesday. The business’s fifty day moving average price is $124.26 and its 200 day moving average price is $120.54. Illumina has a twelve month low of $89.00 and a twelve month high of $148.19. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $20.74 billion, a P/E ratio of -15.98 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the firm posted $0.32 earnings per share. Illumina’s revenue was down 5.4% on a year-over-year basis.

Institutional Investors Weigh In On Illumina

Institutional investors and hedge funds have recently made changes to their positions in the company. Trivant Custom Portfolio Group LLC increased its stake in Illumina by 166.7% during the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 125 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. acquired a new stake in Illumina during the second quarter worth about $34,000. Massmutual Trust Co. FSB ADV boosted its stake in Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after acquiring an additional 132 shares during the period. Finally, Principal Securities Inc. bought a new position in shares of Illumina during the fourth quarter valued at approximately $51,000. 89.42% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.